- Home
- FGI vs KPRX Comparison
FGI vs KPRX Comparison
Compare FGI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- KPRX
- Stock Information
- Founded
- FGI 1987
- KPRX 1998
- Country
- FGI United States
- KPRX United States
- Employees
- FGI N/A
- KPRX N/A
- Industry
- FGI Industrial Specialties
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FGI Industrials
- KPRX Health Care
- Exchange
- FGI Nasdaq
- KPRX Nasdaq
- Market Cap
- FGI 7.9M
- KPRX 8.7M
- IPO Year
- FGI 2022
- KPRX N/A
- Fundamental
- Price
- FGI $3.85
- KPRX $2.69
- Analyst Decision
- FGI
- KPRX Strong Buy
- Analyst Count
- FGI 0
- KPRX 1
- Target Price
- FGI N/A
- KPRX $10.00
- AVG Volume (30 Days)
- FGI 45.5K
- KPRX 80.3K
- Earning Date
- FGI 08-11-2025
- KPRX 11-07-2025
- Dividend Yield
- FGI N/A
- KPRX N/A
- EPS Growth
- FGI N/A
- KPRX N/A
- EPS
- FGI N/A
- KPRX N/A
- Revenue
- FGI $135,904,413.00
- KPRX N/A
- Revenue This Year
- FGI $5.57
- KPRX N/A
- Revenue Next Year
- FGI $8.02
- KPRX N/A
- P/E Ratio
- FGI N/A
- KPRX N/A
- Revenue Growth
- FGI 12.30
- KPRX N/A
- 52 Week Low
- FGI $2.28
- KPRX $2.25
- 52 Week High
- FGI $5.50
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- FGI 47.07
- KPRX 47.63
- Support Level
- FGI $3.52
- KPRX $2.67
- Resistance Level
- FGI $4.16
- KPRX $2.90
- Average True Range (ATR)
- FGI 0.27
- KPRX 0.13
- MACD
- FGI -0.02
- KPRX 0.01
- Stochastic Oscillator
- FGI 39.47
- KPRX 42.11
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.